A lifetime ago, in May 2020, I had the honor of writing my first “From the Trenches” blog. I highlighted our long-range planning (LRP) approach at Xilio Therapeutics reframed as Leaders Require Purpose. I shared our belief that aligning our long and mid-range planning efforts to our vision and values would guide us through the ups and downs of developing innovative oncology treatments for the patients we serve. I posited that having this shared understanding would help us be more proactive vs. reactive. I ended that blog with the “stay tuned” teaser that we were continuing that process remotely and would be conducting our entire company offsite virtually.
This blog was written by Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC.
I have been privileged to read and write for this LifeSciVC blog for a handful of years now. One of my favorite editions is Leave a Ladder Down from Ros Deegan in 2019, both because I was amazed by her knowledge of the Khumbu Icefall in Nepal and because I like the image of leaving a ladder down to help others up as we navigate the inevitable career ladder.
By Samantha Truex, CEO of QuenchBio, as part of the From The Trenches feature of LifeSciVC.
We’re half way through one of the craziest years in recent memory, with a raging viral pandemic, civil unrest and protests, staggering unemployment and economic woes, and invasive murder hornets. And yet, like the indefatigable Energizer bunny, the biotech market just keeps marching onwards and upwards.
“Hey, you know, breakdowns come. And breakdowns go. So what are you going to do about it? That’s what I’d like to know – Gumboots
In an era of COVID, political uncertainty, and market volatility, exhibiting resilience and staying true to our values and mission is a tall order. That notwithstanding, the Paul Simon song that our CSO has quoted since we founded Spero had it right. As leaders, we must supersede these challenges to instill resilience on an organizational level to navigate the twists and turns of getting medicines to patients. The value creation of biotech is in part what we’ve planned for, but also (and often more importantly) how we react when the unexpected happens.
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.
It is a strange time to work in the biotech industry.
National unemployment has spiked to 11%, the Federal Reserve Bank of Atlanta predicts a 35% drop in US GDP in the second quarter, and yet the XBI index of biotech stocks has risen by more than 20% since the beginning of March, when the pandemic threat became apparent in the US.